T1	Participants 175 186	36 patients
T2	Participants 47 159	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
T3	Participants 561 626	patients with disease progression after a TKI-everolimus sequence
T4	Participants 672 777	patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites.
T5	Participants 860 911	patients treated with a TKI-everolimus-TKI sequence
